Market News Call

Special News Alert: Inovio Pharmaceuticals Inc(NYSEMKT:INO), Illumina, Inc. (NASDAQ:ILMN), Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Lakeway, NY — (MARKET NEWS CALL) — 1/16/2014 —, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Inovio Pharmaceuticals Inc(NYSEMKT:INO), Illumina, Inc. (NASDAQ:ILMN), Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Inovio Pharmaceuticals Inc(NYSEMKT:INO) shares fell 0.41% and closed at $2.44. The company announced that Dr. J. Joseph Kim, President and CEO, will present a corporate overview of the company at the Biotech Showcase 2014 investor conference in San Francisco, CA. Biotech Showcase 2014 is on January 13-15 at Parc55 Hotel, San Francisco, CA. A live webcast of Dr. Kim’s Biotech Showcase presentation can be accessed at the following URL:

Should Investors Buy INO After Yesterday’s Slump? Find Out Here

Illumina, Inc. (NASDAQ:ILMN) shares declined 0.32% to $121.12. The company on Jan. 15 announced it has entered into an agreement with Amgen Inc. to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab), a fully human anti-EGFR monoclonal antibody therapeutic for the treatment of metastatic colorectal cancer approved in the US and EU. Under the terms of the collaboration, premarket approval of the test by the US Food and Drug Administration (FDA) and other regulatory bodies will be sought. The test will be developed for use with Illumina’s MiSeqDx™ instrument, which received premarket clearance from the FDA on November 19, 2013 and was CE-marked for the European Union on July 16, 2013.

Can Traders Buy ILMN After The Solid Rally? Get Free Trend Analysis Here

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares decreased 0.29% to $27.57. The company on Dec. 10 announced positive results from a preclinical combination study of CDX-301 (FMS-like tyrosine kinase-3 ligand or Flt3L) and Mozobil(R) (Plerixafor injection, formerly AMD3100) demonstrating that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice. The data support future clinical development of CDX-301 and demonstrate a novel potent cell mobilization regimen combining CDX-301 and Mozobil(R), which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation.

Should Investors Buy CLDX After Yesterday’s Slump? Find Out Here

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.


Tags: , , , ,

Leave your comment here